Novartis’ (NOVN: VX) USA-based generics division Sandoz has resubmitted a US application for a biosimilar version of pegfilgrastim.
The product, which references Amgen’s (Nasdaq: AMGN) Neulasta, is already approved in Europe, where it is marketed as Ziextenzo.
The firm presented positive Phase III data for the candidate in 2015, showing the therapy met its safety and efficacy goals, but was rebuffed by the US regulator in June 2016.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze